Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  deferasirox
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-10 of 10 for your search:
Start Over
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
Phase: Phase II
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CICL670A2302, 2009-012418-38, NCT00940602
Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CICL670A2421, NCT01868477
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Phase: Phase II
Type: Supportive care
Status: Active
Age: Over 18 to 80
Sponsor: Other
Protocol IDs: 2012/2139, NCT01892644
Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: CICL670ACA02T, NCT02038816
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 10 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CICL670F2201, NCT02125877
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CICL670AUS47, NCT02159040
Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65
Phase: Phase II
Type: Treatment
Status: Active
Age: 65 and over
Sponsor: Other
Protocol IDs: 204961, NCT02341495
The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens
Phase: Phase I
Type: Treatment
Status: Approved-not yet active
Age: 15 and over
Sponsor: Other
Protocol IDs: 78001, NCT02413021
Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FISM-BIOFER12, NCT01956799
Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)
Phase: No phase specified
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 40413, NCT02233504
Start Over